ASR vs CR

ASR exhibits strong financial health with a Piotroski F-Score of 7/9, indicating solid operational and balance sheet strength. Profitability metrics are robust, with high margins and ROE above sector average, while leverage remains low. However, recent earnings declines and poor earnings surprise trends—four consecutive misses with double-digit negative surprises—raise concerns about near-term execution. The stock trades significantly above the Graham Number of $64.05, reflecting premium valuation despite weak earnings growth, though it aligns more closely with the growth-based intrinsic value of $181.09.

CR demonstrates stable financial health with a Piotroski F-Score of 6/9 and exceptional liquidity, evidenced by a Current Ratio of 5.53. However, the stock is trading at a severe premium, with the current price of $180.08 vastly exceeding both the Graham Number ($67.44) and the growth-based Intrinsic Value ($41.25). While the company maintains a stellar track record of earnings beats over 25 quarters, the technical trend is currently bearish (0/100) and YoY earnings growth is nearly stagnant at 0.20%. The disconnect between fundamental value and market price suggests a high-quality business that is currently overvalued.